Trial Profile

A Randomized, Controlled, Double-Blind Study the Effect of Futibatinib on QT/QTc Interval

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Futibatinib (Primary) ; Moxifloxacin
Indications Breast cancer; Cholangiocarcinoma; Gastric cancer; Lymphoid leukaemia; Myeloid leukaemia; Solid tumours; Urogenital cancer
Focus Pharmacodynamics

Most Recent Events

01 Mar 2023 Results assessing the time-matched difference in change from baseline in QTcF (ddQTcF) between futibatinib and placebo, published in the Clinical Pharmacology in Drug Development.
26 May 2021 New trial record
10 Apr 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com